Zevra Therapeutics (ZVRA) Net Cash Flow (2014 - 2026)

Zevra Therapeutics (ZVRA) has 13 years of Net Cash Flow data on file, last reported at $33.0 million in Q1 2026.

• Quarterly Net Cash Flow rose 739.22% year-over-year to $33.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.6 million (up 1122.39% YoY) and the FY2025 annual result came in at $28.6 million, up 394.23% from the prior year.
• Net Cash Flow advanced to $33.0 million in Q1 2026, from $8.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $33.0 million in Q1 2026 to a low of -$25.3 million in Q1 2023.
• A 5-year average of -$1.0 million and a median of -$569000.0 in 2023 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2024 — Net Cash Flow sank 3577.5% — and 2025, when it surged 2633.55%.
• Tracing ZVRA's Net Cash Flow over 5 years: stood at -$4.8 million in 2022, then soared by 88.27% to -$569000.0 in 2023, then slumped by 3577.5% to -$20.9 million in 2024, then soared by 139.61% to $8.3 million in 2025, then soared by 297.59% to $33.0 million in 2026.
• The last three Net Cash Flow figures came in at $33.0 million (Q1 2026), $8.3 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.